Analyst Yanan Zhu of Wells Fargo maintained a Hold rating on Sangamo Biosciences (SGMO – Research Report), retaining the price target of $2.00. Discover outperforming stocks and invest smarter ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
NEW YORK, NY / ACCESSWIRE / January 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo Therapeutics, Inc. ("Sangamo Therapeutics, Inc.") (NASDAQ ...
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a biotechnology company specializing in genomic medicine and gene therapies, stands at a critical juncture as it navigates a complex landscape of clinical ...
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sangamo Therapeutics ...
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) on behalf of investors ...
Shares of Sangamo Therapeutics have plummeted more than 56% over the past few days after Pfizer announced it had terminated its partnership to develop an investigational gene therapy product to treat ...
RICHMOND, Calif. - Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company with a market capitalization of $492 million, today announced the forthcoming reacquisition of development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback